Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. 

CEO
Douglas S. Ingram
CEODouglas S. Ingram
Employees
1,372
Employees1,372
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
1,372
Employees1,372

SRPT Key Statistics

Market cap
1.26B
Market cap1.26B
Price-Earnings ratio
-5.00
Price-Earnings ratio-5.00
Dividend yield
—
Dividend yield—
Average volume
22.53M
Average volume22.53M
High today
$13.82
High today$13.82
Low today
$10.42
Low today$10.42
Open price
$12.78
Open price$12.78
Volume
44.55M
Volume44.55M
52 Week high
$150.48
52 Week high$150.48
52 Week low
$10.42
52 Week low$10.42

SRPT News

Seeking Alpha 11h
Sarepta drops as report suggests FDA needs new trials for Elevidys

Sarepta Therapeutics (NASDAQ:SRPT) resumed its recent sell-off on Thursday after Endpoints News reported that the FDA would require the company to conduct new s...

Sarepta drops as report suggests FDA needs new trials for Elevidys
Seeking Alpha 2d
Arrowhead expects Sarepta to honor financial obligations

Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced Wednesday that it expects its partner Sarepta Therapeutics (NASDAQ:SRPT), which recently withdrew its gene the...

Arrowhead expects Sarepta to honor financial obligations
Seeking Alpha 2d
Roche pauses Sarepta gene therapy shipments outside the U.S.

Roche (OTCQX:RHHBY) has decided to pause overseas shipments of Elevidys gene therapy developed by Sarepta Therapeutics (NASDAQ:SRPT) following safety concerns r...

Roche pauses Sarepta gene therapy shipments outside the U.S.

Analyst ratings

67%

of 27 ratings
Buy
18.5%
Hold
66.7%
Sell
14.8%

More SRPT News

Washington Post 6d
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - The Washington Post

...

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - The Washington Post
Sherwood News 6d
Sarepta dives on reports that FDA will ask it to stop selling gene treatment

The Food and Drug Administration will request Sarepta Therapeutics to stop all shipments of its most lucrative drug after it disclosed last month that a second...

Sarepta dives on reports that FDA will ask it to stop selling gene treatment
CNBC 6d
Sarepta shares plunge 30% as future of its gene therapy appears at risk

Douglas Ingram, president and chief executive officer of Sarepta Therapeutics Inc., during the Forbes Healthcare Summit in New York, US, on Tuesday, Dec. 5, 202...

Sarepta shares plunge 30% as future of its gene therapy appears at risk
TipRanks 6d
Sarepta downgraded to Hold from Buy at Needham

Needham analyst Gil Blum downgraded Sarepta (SRPT) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

Benzinga 6d
Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta Therapeutics SRPT shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding...

Sarepta's Setback Deepens With Another Gene Therapy Fatality
TipRanks 7d
Sarepta CEO says didn’t disclose patient death on Weds. call, ‘wasn’t salient’

The company, on an update conference call, says it didn’t disclose the limb girdle patient death on the Wednesday update call as it “wasn’t salient to our discu...

Benzinga 7d
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Shares of Sarepta Therapeutics SRPT plunged over 30% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marki...

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.
UnitedHealth
Moderna
Enphase Energy
Centene
CRISPR
Micron Technology
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.